Evidence map›Paper›PMID 25613571›Full record

ArticleCell research2015

Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response.

Xiawei Wei, Bin Shao, Zhiyao He, Tinghong Ye, Min Luo, Yaxiong Sang, Xiao Liang, Wei Wang, Shuntao Luo, Shengyong Yang and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Cell research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 287 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. PEG-NHInternational journal of nanomedicine · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases.Molecular therapy. Methods & clinical development · 2025
    Review
  19. Review
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 2 countries.

Xiawei WeiKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Bin ShaoKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Zhiyao HeKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Tinghong YeKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Min LuoKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Yaxiong SangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Xiao LiangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Wei WangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Shuntao LuoKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Shengyong YangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Shuang ZhangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Changyang GongKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Maling GouKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Hongxing DengKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Yinglan ZhaoKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Hanshuo YangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Senyi DengKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Chengjian ZhaoKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Li YangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Zhiyong QianKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Jiong LiKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Xun SunKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
Jiahuai HanState Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361005, China.
Chengyu JiangState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Biochemistry and Molecular Biology, Peking Union Medical College, Beijing 100005, China.
Min WuDepartment of Biochemistry and Molecular Biology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Zhirong ZhangKey Laboratory of Drug Targeting of Ministry of Education, State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, China.
University of North Dakota · USXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanocarriers with positive surface charges are known for their toxicity which has limited their clinical applications. The mechanism underlying their toxicity, such as the induction of inflammatory response, remains largely unknown. In the present study we found that injection of cationic nanocarriers, including cationic liposomes, PEI, and chitosan, led to the rapid appearance of necrotic cells. Cell necrosis induced by cationic nanocarriers is dependent on their positive surface charges, but does not require RIP1 and Mlkl. Instead, intracellular Na(+) overload was found to accompany the cell death. Depletion of Na(+) in culture medium or pretreatment of cells with the Na(+)/K(+)-ATPase cation-binding site inhibitor ouabain, protected cells from cell necrosis. Moreover, treatment with cationic nanocarriers inhibited Na(+)/K(+)-ATPase activity both in vitro and in vivo. The computational simulation showed that cationic carriers could interact with cation-binding site of Na(+)/K(+)-ATPase. Mice pretreated with a small dose of ouabain showed improved survival after injection of a lethal dose of cationic nanocarriers. Further analyses suggest that cell necrosis induced by cationic nanocarriers and the resulting leakage of mitochondrial DNA could trigger severe inflammation in vivo, which is mediated by a pathway involving TLR9 and MyD88 signaling. Taken together, our results reveal a novel mechanism whereby cationic nanocarriers induce acute cell necrosis through the interaction with Na(+)/K(+)-ATPase, with the subsequent exposure of mitochondrial damage-associated molecular patterns as a key event that mediates the inflammatory responses. Our study has important implications for evaluating the biocompatibility of nanocarriers and designing better and safer ones for drug delivery.

Indexed as

NecrosisAnimalsApoptosisCationsCell Line, TumorChitosanDNA, MitochondrialDrug CarriersHumansInflammationLiposomesMiceMice, Inbred C57BLMice, KnockoutMitochondriaMyeloid Differentiation Factor 88CationsChitosanDNA, MitochondrialDrug CarriersLiposomesMyeloid Differentiation Factor 88OuabainPolyethyleneimineSodium-Potassium-Exchanging ATPaseTLR9 protein, humanToll-Like Receptor 9

Identifiers

PMID25613571
PMCPMC4650577
OpenAlexW2049263710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.